Fundraisings and IPOs

Date: 2018-11-26

Type of information: Series D financing round

Company: Adrenomed (Germany)

Investors: HBM Healthcare Investments (Switzerland) Wellington Partners (Germany - UK)

Amount: € 24 million

Funding type: series D financing round

Planned used:

  • The new funds will be invested in the clinical development program of lead product candidate adrecizumab. Adrecizumab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma adrenomedullin concentrations (bio-ADM®). This first-in-class monoclonal antibody is targeting adrenomedullin, an essential regulator of vascular integrity, for treatment of life-threatening conditions associated with systemic inflammatory response (SIRS) and increased vascular leakage, congestion and shock. The most important target indications are sepsis and septic shock.


  • • On November 26t, 2018, Adrenomed, the vascular integrity company, announced the closing of a € 24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors.

Therapeutic area: Inflammatory diseases

Is general: Yes